SREBF2 and Miyoshi myopathy: Since these initial observations in AML and MM, dipyridamole has been shown to inhibit statin‐induced SREBP2 activation and potentiate statin‐induced cell death in breast [3] and prostate [4] cancer; however, the mechanism by which dipyridamole inhibits SREBP2 and potentiates statin‐induced cancer cell death remains poorly characterized.